CAS: 322-79-2; 2-Acetoxy-4-(Trifluoromethyl)Benzoic Acid

该化合物是一个主要因其抗板特性而得到承认的化学化合物,它有助于预防血栓栓状体紊乱,被归类为非类固醇抗炎药物,在结构上与盐酸有关,三氟化硫通过调制环氧基酶活动和抑制Troomboxane A2合成物抑制聚积,展示了一种独特的行动机制,它通过调制环氧基酶活动和抑制Tromboxane A2合成物来抑制聚积.这种化合物通常以口头方式施用,并因其与传统的非典物质ID相比胃肠毒性较低而闻名.除了其抗板状效应外,三氟化物还具有抗炎和止痛特性,有助于其治疗应用.该物质一般都受到很好的调剂,但和所有药物一样,它可能具有副作用,包括胃肠扰动或某些个人的过敏反应.其药理学学学涉及快速吸收和代谢,导致相对短的半衰期,因此需要需要谨慎地保持治疗.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

4-三氟甲基水杨酸 4-Trifluoromethylsalicylic Acid 328-90-5

合成工艺路线路线简述

    间三氟甲基苯酚置于potassium Carbonate体系中,化学反应生成 三氟柳
    参考文献:Attachment Behaviors,Depression,And Anxiety In Nonoffending Mothers Of Child Sexual Abuse Victims
    标题:Attachment Behaviors,Depression,And Anxiety In Nonoffending Mothers Of Child Sexual Abuse Victims
    摘要:本研究的目的是研究未参与虐待的儿童性侵受害者(csavs)的母亲的心理幸福感和依恋行为.这个主题很重要,因为通常是母亲最经常为年幼的受害儿童提供支持.分析了关于母亲抑郁症,状态和特质焦虑以及ainsworth母亲依恋行为的两组数据.首先,根据母亲是否有虐待史,比较了38位csavs的母亲.其次,从最初的38位csavs的母亲中,比较了27位母亲与一组非受虐儿童的母亲.两组数据中的儿童年龄为6至48个月.在第一组数据中,根据母亲个人虐待史,抑郁症,焦虑和依恋行为没有显著差异.然而,在第二组数据中,Csavs的母亲抑郁和焦虑水平升高,母亲依恋行为减弱.
    DOI:10.1177/1077559501006004009

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-8420850-B2
    优先权日:2010-05-14
    标 题:Compounds for the synthesis of biostable polyurethane, polyurea or polyurea urethane polymers
    发明人:DUOCASTELLA CODINA LLUIS; MOLINA MARIA; ARAD OFIR; BORRELL BILBAO JOSE IGNACIO; GARCIA DAVID SANCHEZ; PETTERSON SALOM SOFIA HENRIETTE
    权利人:DUOCASTELLA CODINA LLUIS; MOLINA MARIA; ARAD OFIR; BORRELL BILBAO JOSE IGNACIO; GARCIA DAVID SANCHEZ; PETTERSON SALOM SOFIA HENRIETTE; IBERHOSPITEX SA
    摘要:The invention comprises compounds which are derived from a drug or a substance with therapeutic properties, and useful as reagents for the synthesis of biostable polymers including said drug in their backbone, namely polyurethanes, polyureas or polyurea urethanes that are biocompatible and biostable. The invention also comprises the processes for preparing the compounds and the polymers, and to the use of these polymers for the manufacture of medical devices.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-6930113-B2
    优先权日:1996-11-01
    标题 :Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
    发明人:GARVEY DAVID S; DE TEJADA INIGO SAENZ; EARL RICHARD A; KHANAPURE SUBHASH P
    权利人:NITROMED INC
    摘要:The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides novel compositions containing at least one phosphodiesterase inhibitor, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing diseases induced by the increased metabolism of cyclic guanosine 3′,5′-monophosphate (cGMP), such as hypertension, pulmonary hypertension, congestive heart failure, renal failure, myocardial infraction, stable, unstable and variant (Prinzmetal) angina, atherosclerosis, cardiac edema, renal insufficiency, nephrotic edema, hepatic edema, stroke, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, dementia, immunodeficiency, premature labor, dysmenorrhoea, benign prostatic hyperplasis (BPH), bladder outlet obstruction, incontinence, conditions of reduced blood vessel patency, e.g., postpercutaneous transluminal coronary angioplasty (post-PTCA), peripheral vascular disease, allergic rhinitis, glucoma, and diseases characterized by disorders of gut motility, e.g., irritable bowel syndrome (IBS).

    专利号:US-2003203915-A1
    优先权日:2002-04-05
    标题 :Nitric oxide donors, compositions and methods of use related applications
    发明人:FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
    权利人:FANG XINQIN; GARVEY DAVID S; GASTON RICKY D; LIN CHIA-EN; RANATUNGA RAMANI R; RICHARDSON STEWART K; WANG TIANSHENG; WANG WEIHENG; WEY SHIOW-JYI
    摘要:The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO 2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

    专利号:US-2003158184-A1
    优先权日:2001-12-21
    标 题 :Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
    发明人:GARVEY DAVID S; DE TEJADA INIGO SAENZ
    摘要:The invention provides methods for treating female sexual dysfunctions by administering to a female individual a therapeutically effective amount of at least one compound that donates, transfers or release nitrogen monoxide, that induces the production of endogenous endothelium-derived relaxing factor, that stimulates endogenous synthesis of nitrogen monoxide, or that is a substrate for nitric oxide synthase. The methods may further comprise administering a therapeutically effective amount of a phosphodiesterase inhibitor and/or a nitrosated and/or nitrosylated phosphodiesterase inhibitor.
    浙江燎原药业有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.liaoyuan.com.cn
    企业联系电话:86-576-85300990,85308861,85300959👤
    📞浙江燎原药业有限公司 ⚠️参考联系方式
    联系人:张鹏
    电话:86-576-85300990,85308861,85300959

    传真:86-576-85302808
    邮箱:alanzp@liaoyuan.com.cn
    通信地址: 浙江省临海市靖江花城9号楼3F
    邮编: 317000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省临海市靖江花城9号楼3F
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    广东中科药物研究有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zonk.cn
    电话: 020-32051076 13922751178👤
    📞广东中科药物研究有限公司 ⚠️参考联系方式

    销售电话:020-32051076 13922751178
    邮箱:nzwangwei@hotmail.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    湖北恒硕化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.hengshuochem.com
    企业联系电话:027-82200625;82830253👤
    📞湖北恒硕化工有限公司 ⚠️参考联系方式
    联系人:王硕 徐文琪
    电话:027-82200625;82830253
    手机:13986271535;13995541600
    传真:027-82830253
    邮箱:hengshuochem@163.com
    通信地址: 湖北省武汉市临空港经济技术开发区碧水大道7号飘轩工业园
    邮编: 430014
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:湖北省武汉市临空港经济技术开发区碧水大道7号飘轩工业园
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    青岛和兴精细化学有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.unionfinechem.com
    企业联系电话:0532-66915948 66918817👤
    📞青岛和兴精细化学有限公司 ⚠️参考联系方式

    电话:0532-66915948 66918817

    传真:0532-66916851
    邮箱:info@unionfinechem.com
    通信地址: 青岛市重庆北路7号
    邮编: 266108
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:青岛市重庆北路7号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, Tselepis AD. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024 Sep 21;25(18):10136. doi: 10.3390/ijms251810136.
    2: Bonet-Monné S, Urgell CV, Sáez MJP, Puertolás OC, Baena-Díez JM, Pascual J, Lago CO, Ruiz JR, Gonzalez BS, Pedrós RM. NSAIDs, analgesics, antiplatelet drugs, and decline in renal function: a retrospective case-control study with SIDIAP database. BMC Pharmacol Toxicol. 2024 Aug 28;25(1):58. doi: 10.1186/s40360-024-00771-5.
    3: Prieto-Campo Á, Zapata-Cachafeiro M, Portela-Romero M, Piñeiro-Lamas M, Figueiras A, Salgado-Barreira Á. Impact of prior use of antiplatelets on COVID-19 susceptibility, progression, and severity: a population-based study. Rev Esp Cardiol (Engl Ed). 2024 Jul;77(7):539-546. English, Spanish. doi: 10.1016/j.rec.2023.12.004. Epub 2024 Jan 6. 26(3):105284. doi: 10.1016/j.micinf.2023.105284. Epub 2023 Dec 23.

    合成参考文献


    参考文献:10.4321/s1130-01082011000700005
    摘要:Wikman-Jorgensen P, López-Calleja E, Safont-Gasó P, Matarranz-del-Amo M, Andrés-Navarro R, Merino-Sánchez J. Antiagregation and anticoagulation, relationship with upper gastrointestinal bleeding. Rev. esp. enferm. dig. 2011 Jul;103(7):360–5. doi: 10.4321/s1130-01082011000700005.
    参考文献:10.3389/fneur.2011.00036
    摘要:Shulga O, Bornstein N. Antiplatelets in secondary stroke prevention. Front Neurol. 2011;2():36.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知